Table 2.

Targeted antigens in solid tumor CAR T cell therapy (in vitro studies)

Cancer	Antigen
Colorectal	NKG2D [54], EP-CAM [55], HER2 [56], GUCY2C [57], TAG-72 [58], CD46 [58]
Liver	CEA [59], Glypican3 [60], AFP [61]
Gastric	Mesothelin [62], ANTXR1 [63], MUC3A [63], Trop2 [64], Claudin18.2 [66], NKG2D [28], HER2 [65, 66], FR-α [67]
Pancreatic	MUC1 [68], Mesothelin [69], αvβ6 [70], CEA [71], PSCA [71], FAP [71], CD47 [72], HER2 [73], NKG2D [74]
Renal	CAIX [75]
Melanoma	GD2 [76], GSPG4 [77], Glypican3 [78], HER2 [79]
Cervix	αvβ6 [80], L1-CAM [81]
Neuroblastoma	GD2 [82, 83], CD56 [84], Glypican 2 [85], CD171 [86]
Glioblastoma	EGFRvIII [87], HER2 [88], B7-H3 [89], NKG2D [90], CAIX [91], αvβ3, IL13Rα2 [92]
Ovarian	Mesothelin [62, 93], αvβ6 [94], B7-H3 [95], CD47 [72], NKG2D [96]
Prostate	PSA [97], PAP [97], PSCA [98], PSMA [99], EpCAM [100]
Lung	MAGE-A1 [101], CD32A [102], ROR [103], EGFRvIII [104]
Head and neck	HER2 [105]

NKG2D natural killer group 2, member D receptor, EpCAM epithelial cell adhesion molecule, HER2 human epidermal growth factor receptor 2, PSCA prostate stem cell antigen, MUC1 mucin1, AFP alpha-fetoprotein, FAP familial adenomatous polyposis, CEA carcinoembryonic antigen, MUC16 mucin16, PSMA prostate-specific membrane antigen, CAIX carbonic anhydrase IX, FRα folate receptor alpha, TAG-72 tumor-associated glycoprotein 72, MAGE melanoma antigen gene protein, GUCY2C guanylate cyclase 2C, ANTXR1 anthrax toxin receptor 1, GSPG4; general secretion pathway protein G, PSA prostate-specific antigen, ROR RAR-related orphan receptors